Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)
China · Delayed Price · Currency is CNY 40.30
+0.32 (0.80%)
Oct 30, 2026, 3:00 PM CST
SHA:600329 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 4,665 | 4,917 | 7,307 | 8,222 | 8,249 | 6,908 |
Revenue Growth | -13.05% | -32.70% | -11.13% | -0.33% | 19.42% | 4.60% |
Gross Profit Gross Profit Growth | 3,457 | 3,605 | 3,503 | 3,590 | 3,258 | 2,747 |
Operating Income Operating Income Growth | 1,115 | 917.86 | 774.04 | 821.03 | 671.32 | 587.04 |
Net Income Net Income Growth | 895.67 | 2,131 | 2,229 | 986.71 | 861.79 | 769.14 |
Earnings Per Share EPS Growth | 1.16 | 2.77 | 2.89 | 1.28 | 1.11 | 1.00 |
EPS Growth | -75.05% | -4.15% | 125.78% | 15.32% | 11.00% | 16.28% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Chinese Patent Medicine Chinese Patent Medicine Growth | 4,300 | 4,461 | 5,657 | 5,836 | 5,652 | 4,670 |
Western Medicine Western Medicine Growth | 69.89 | 89.94 | 1,192 | 1,697 | 1,783 | 1,596 |
Others Others Growth | 376.58 | 366.23 | 457.4 | 673.08 | 796.26 | 626.9 |
Total Total Growth | 4,721 | 4,917 | 7,307 | 8,206 | 8,231 | 6,892 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,314 | 4,332 | 3,945 | 2,187 | 2,923 | 2,393 |
Total Debt Total Debt Growth | 94.91 | 75.68 | 38.59 | 339.14 | 267.91 | 43.17 |
Net Cash (Debt) Net Cash Growth | 1,220 | 4,257 | 3,906 | 1,848 | 2,655 | 2,350 |
Net Cash Growth | -28.82% | 8.98% | 111.39% | -30.41% | 13.01% | 20.83% |
Net Cash Per Share Net Cash Per Share Growth | 1.58 | 5.53 | 5.06 | 2.40 | 3.42 | 3.05 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 726.76 | 461.07 | 924.67 | 688.49 | 677.25 | 852.4 |
Capital Expenditures CapEx Growth | -134.23 | -118.61 | -117.81 | -140.93 | -107.9 | -156.95 |
Free Cash Flow Free Cash Flow Growth | 592.53 | 342.45 | 806.86 | 547.56 | 569.34 | 695.45 |
Free Cash Flow Growth | -30.00% | -57.56% | 47.36% | -3.83% | -18.13% | 44.21% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 74.11% | 73.31% | 47.94% | 43.66% | 39.49% | 39.77% |
Operating Margin | 23.90% | 18.67% | 10.59% | 9.98% | 8.14% | 8.50% |
Pretax Margin | 22.03% | 50.59% | 35.29% | 13.32% | 11.88% | 12.64% |
Profit Margin | 19.20% | 43.34% | 30.51% | 12.00% | 10.45% | 11.13% |
FCF Margin | 12.70% | 6.96% | 11.04% | 6.66% | 6.90% | 10.07% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 4.680 | 4.790 | 1.280 | 1.280 | 1.120 | 0.500 |
Dividend Per Share Growth | 274.22% | 274.22% | 0% | 14.29% | 124.00% | 66.67% |
Dividend Yield | 11.61% | 11.98% | 4.76% | 4.46% | 4.75% | 1.99% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 36.47 | 14.44 | 9.29 | 22.42 | 21.17 | 25.32 |
Forward PE | 30.07 | 24.66 | 18.40 | 20.04 | 22.73 | 22.87 |
P/FCF Ratio | 38.16 | 89.88 | 25.65 | 40.40 | 32.05 | 28.00 |
PS Ratio | 5.60 | 6.26 | 2.83 | 2.69 | 2.21 | 2.82 |